Abdominal aortic aneurysms targeted by functionalized polysaccharide microparticles: A new tool for SPECT imaging

Theranostics

Volumn 4, Issue 6, 2014, Pages 592-603

  Bonnard, Thomas ^a,b   Yang, Gonord ^a   Petiet, Anne ^c   Ollivier, Véronique ^a   Haddad, Oualid ^d   Arnaud, Denis ^a   Louedec, Liliane ^a   Bachelet Violette, Laure ^a   Derkaoui, Sidi Mohammed ^a   Letourneur, Didier ^a,b   Chauvierre, Cedric ^a   Le Visage, Catherine ^a  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

Fucoidan; Ligand; P selectin; Radiolabeled

Indexed keywords

DEXTRAN TC 99M; FUCOIDAN TC 99M; PADGEM PROTEIN; PULLULAN TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; FUCOIDIN; MICROSPHERE; POLYSACCHARIDE; TECHNETIUM;

ABDOMINAL AORTA ANEURYSM; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; EARLY DIAGNOSIS; HEMOLYSIS; ISOTOPE LABELING; MALE; MOLECULAR INTERACTION; NONHUMAN; PARTICLE SIZE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIOACTIVITY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ZETA POTENTIAL; ANIMAL; AORTA; CHEMISTRY; DIAGNOSTIC USE; HUMAN; METABOLISM; SCINTISCANNING; THROMBOCYTE; WISTAR RAT;

ANIMALS; AORTA; AORTIC ANEURYSM, ABDOMINAL; BLOOD PLATELETS; HUMANS; MALE; MICROSPHERES; P-SELECTIN; POLYSACCHARIDES; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84902439619     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7757     Document Type: Article

References (72)

1. Van der Vliet JA, Boll AP. Abdominal aortic aneurysm. Lancet. 1997; 349: 863-6.
2. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011; 8: 92-102.
3. Hong H, Yang Y, Liu B, Cai W. Imaging of Abdominal Aortic Aneurysm: the present and the future. Curr Vasc Pharmacol. 2010; 8: 808-19.
4. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008; 118: 2382-92.
5. Wassef M, Upchurch GR, Jr., Kuivaniemi H, Thompson RW, Tilson MD, 3rd. Challenges and opportunities in abdominal aortic aneurysm research. J Vasc Surg. 2007; 45: 192-8.
6. Klink A, Hyafil F, Rudd J, Faries P, Fuster V, Mallat Z, et al. Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nat Rev Cardiol. 2011; 8: 338-47.
7. Annambhotla S, Bourgeois S, Wang X, Lin PH, Yao Q, Chen C. Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J Surg. 2008; 32: 976-86.
8. Bazeli R, Coutard M, Duport BD, Lancelot E, Corot C, Laissy JP, et al. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2010; 45: 662-8.
9. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov. 2004; 3: 913-25.
10. Klink A, Heynens J, Herranz B, Lobatto ME, Arias T, Sanders HM, et al. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol. 2011; 58: 2522-30.
11. Makowski MR, Preissel A, von Bary C, Warley A, Schachoff S, Keithan A, et al. Three-dimensional imaging of the aortic vessel wall using an elastin-specific magnetic resonance contrast agent. Invest Radiol. 2012; 47: 438-44.
12. Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol. 2009; 29: 983-91. doi:10.1161/atvbaha.108.165498.
13. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med. 2004; 10: 171-8.
14. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004; 92: 459-66.
15. Yokoyama S, Ikeda H, Haramaki N, Yasukawa H, Murohara T, Imaizumi T. Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. J Am Coll Cardiol. 2005; 45: 1280-6.
16. Hannawa KK, Cho BS, Sinha I, Roelofs KJ, Myers DD, Wakefield TJ, et al. Attenuation of experimental aortic aneurysm formation in P-selectin knockout mice. Ann N Y Acad Sci. 2006; 1085: 353-9.
17. Kona S, Dong JF, Liu Y, Tan J, Nguyen KT. Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. Int J Pharm. 2012; 423: 516-24.
18. van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, Davis BG. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci U S A. 2009; 106: 18-23.
19. McAteer MA, Mankia K, Ruparelia N, Jefferson A, Nugent HB, Stork LA, et al. A leukocyte-mimetic magnetic resonance imaging contrast agent homes rapidly to activated endothelium and tracks with atherosclerotic lesion macrophage content. Arterioscler Thromb Vasc Biol. 2012; 32: 1427-35.
20. Ramaswamy AK, Hamilton M, 2nd, Joshi RV, Kline BP, Li R, Wang P, et al. Molecular imaging of experimental abdominal aortic aneurysms. Scientific World Journal. 2013; 2013: 973150.
21. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein HH, Krause BJ. Increased 18F-fluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg. 2008; 48: 417-23; discussion 24.
22. Sakalihasan N, Hustinx R, Limet R. Contribution of PET scanning to the evaluation of abdominal aortic aneurysm. Semin Vasc Surg. 2004; 17: 144-53.
23. Kotze CW, Groves AM, Menezes LJ, Harvey R, Endozo R, Kayani IA, et al. What is the relationship between (1)(8)F-FDG aortic aneurysm uptake on PET/CT and future growth rate? Eur J Nucl Med Mol Imaging. 2011; 38: 1493-9.
24. Zolle I, Mazzi U, Spies H, Pietzsch HJ, Bringhammar T, Mallol J, et al. Technetium-99m pharmaceuticals: preparation and quality control in nuclear medicine. Vienna, Austria: Springer; 2007.
25. Ryo UY, Pinsky SM. Radionuclide angiography with 99m technetium-RBCs. CRC Crit Rev Clin Radiol Nucl Med. 1976; 8: 107-28.
26. Iwasaki T, Aihara Y, Kanda T, Oriuchi N, Endo K, Katoh H, et al. Immunoscintigraphy of aortic dissection with 99mTc-labeled murine anti-smooth muscle myosin monoclonal antibody in rats. J Nucl Med. 2001; 42: 130-7.
27. Sarda-Mantel L, Coutard M, Rouzet F, Raguin O, Vrigneaud JM, Hervatin F, et al. 99mTc-annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006; 26: 2153-9.
28. Aguilar F, Autrup H, Barlow S, Castle L, Crebelli R, Dekant W, et al. Use of lycopene as a food colour. Scientific opinion of the panel on food additives, flavourings, processing aids and materials in contact with food. Europ Food Saf Authority J. 2008;: 1-66.
29. Fricain JC, Schlaubitz S, Le Visage C, Arnault I, Derkaoui SM, Siadous R, et al. A nano-hydroxyapatite--pullulan/dextran polysaccharide composite macroporous material for bone tissue engineering. Biomaterials. 2013; 34: 2947-59.
30. Shi L, Aid R, Le Visage C, Chew SY. Biomimicking polysaccharide nanofibers promote vascular phenotypes: a potential application for vascular tissue engineering. Macromol Biosci. 2012; 12: 395-401.
31. Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. Molecules. 2008; 13: 1671-95.
32. Rouzet F, Bachelet-Violette L, Alsac JM, Suzuki M, Meulemans A, Louedec L, et al. Radiolabeled Fucoidan as a P-Selectin Targeting Agent for In Vivo Imaging of Platelet-Rich Thrombus and Endothelial Activation. J Nucl Med. 2011; 52: 1433-40.
33. Bachelet L, Bertholon I, Lavigne D, Vassy R, Jandrot-Perrus M, Chaubet F, et al. Affinity of low molecular weight fucoidan for P-selectin triggers its binding to activated human platelets. Biochimica et Biophysica Acta (BBA) - General Subjects. 2009; 1790: 141-6.
34. Lavergne M, Derkaoui M, Delmau C, Letourneur D, Uzan G, Le Visage C. Porous polysaccharide-based scaffolds for human endothelial progenitor cells. Macromol Biosci. 2012; 12: 901-10.
35. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation. 1990; 82: 973-81.
36. Coutard M, Touat Z, Houard X, Leclercq A, Michel JB. Thrombus versus wall biological activities in experimental aortic aneurysms. J Vasc Res. 2010; 47: 355-66.
37. Robinson MS, Colas-Linhart NC, Guiraud-Vitaux FM, Petiet AM, Bok BD. Heterogeneous distribution of technetium-99m-labeled microspheres in rat lungs: microautoradiographic evidence and dosimetric consequences. J Nucl Med. 1997; 38: 650-4.
38. Limited Ht. Fact sheet ILFORD nuclear emulsions. Technical informatioin for particle physics applications. Town Lane: Ilford. 2005: 5.
39. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm. 2010; 7: 1899-912.
40. Svenson S. Theranostics: are we there yet? Mol Pharm. 2013; 10: 848-56.
41. Jung H, Robison AD, Cremer PS. Multivalent ligand-receptor binding on supported lipid bilayers. J Struct Biol. 2009; 168: 90-4.
42. Wang X, Ramstrom O, Yan M. Glyconanomaterials: synthesis, characterization, and ligand presentation. Adv Mater. 2010; 22: 1946-53.
43. Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med. 2010; 40: 220-41.
44. Petit WA, DeLand FH, Pepper GH, Blanton L. Characterization of tin-technetium colloid in technetium-labeled albumin preparations. J Nucl Med. 1978; 19: 387-92.
45. Diez S, Tros de Ilarduya C. Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery. Eur J Pharm Biopharm. 2006; 63: 188-97.
46. Gu YS, Regnier L, McClements DJ. Influence of environmental stresses on stability of oil-in-water emulsions containing droplets stabilized by beta-lactoglobulin-iota-carrageenan membranes. J Colloid Interface Sci. 2005; 286: 551-8.
47. Harnsilawat T, Pongsawatmanit R, McClements DJ. Influence of pH and ionic strength on formation and stability of emulsions containing oil droplets coated by beta-lactoglobulin-alginate interfaces. Biomacromolecules. 2006; 7: 2052-8.
48. Sakhalkar HS, Hanes J, Fu J, Benavides U, Malgor R, Borruso CL, et al. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J. 2005; 19: 792-4.
49. Omolola Eniola A, Hammer DA. In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors. Biomaterials. 2005; 26: 7136-44.
50. Simone EA, Zern BJ, Chacko AM, Mikitsh JL, Blankemeyer ER, Muro S, et al. Endothelial targeting of polymeric nanoparticles stably labeled with the PET imaging radioisotope iodine-124. Biomaterials. 2012; 33: 5406-13.
51. Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model. J Control Release. 1998; 54: 201-11.
52. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 2008; 25: 1815-21. doi:10.1007/s11095-008-9562-y.
53. Eniola-Adefeso O, Heslinga MJ, Porter TM. Design of nanovectors for therapy and imaging of cardiovascular diseases. Methodist Debakey Cardiovasc J. 2012; 8: 13-7.
54. Charoenphol P, Huang RB, Eniola-Adefeso O. Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carriers. Biomaterials. 2010; 31: 1392-402.
55. Shinde Patil VR, Campbell CJ, Yun YH, Slack SM, Goetz DJ. Particle diameter influences adhesion under flow. Biophys J. 2001; 80: 1733-43.
56. Charoenphol P, Mocherla S, Bouis D, Namdee K, Pinsky DJ, Eniola-Adefeso O. Targeting therapeutics to the vascular wall in atherosclerosis--carrier size matters. Atherosclerosis. 2011; 217: 364-70.
57. Mehta P, Cummings RD, McEver RP. Affinity and kinetic analysis of P-selectin binding to P-selectin glycoprotein ligand-1. J Biol Chem. 1998; 273: 32506-13.
58. Dore CM, das CFAMG, Will LS, Costa TG, Sabry DA, de Souza Rego LA, et al. A sulfated polysaccharide, fucans, isolated from brown algae Sargassum vulgare with anticoagulant, antithrombotic, antioxidant and anti-inflammatory effects. Carbohydr Polym. 2013; 91: 467-75.
59. Modery CL, Ravikumar M, Wong TL, Dzuricky MJ, Durongkaveroj N, Sen Gupta A. Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery. Biomaterials. 2011; 32: 9504-14.
60. Sadat U, Taviani V, Patterson AJ, Young VE, Graves MJ, Teng Z, et al. Ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging of abdominal aortic aneurysms--a feasibility study. Eur J Vasc Endovasc Surg. 2011; 41: 167-74.
61. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of abdominal aortic aneurysm progressio. Part 2: inflammation. Nat Rev Cardiol. 2009; 6: 543-52.
62. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest. 2008; 118: 3012-24.
63. Palmieri D, Pane B, Barisione C, Spinella G, Garibaldi S, Ghigliotti G, et al. Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development. J Surg Res. 2011; 171: e237-46.
64. Yao Y, Wang Y, Zhang Y, Li Y, Sheng Z, Wen S, et al. In vivo imaging of macrophages during the early-stages of abdominal aortic aneurysm using high resolution MRI in ApoE mice. PLoS One. 2012; 7: e33523.
65. Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996; 88: 3259-87.
66. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj J. 1997; 14: 585-91.
67. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005; 11: 1330-8.
68. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg. 2001; 33: 1057-64.
69. Lee S, Kim K. Protease activity: meeting its theranostic potential. Theranostics. 2012; 2: 125-6.
70. Choi KY, Swierczewska M, Lee S, Chen X. Protease-activated drug development. Theranostics. 2012; 2: 156-78.
71. Le Visage C, Gournay O, Benguirat N, Hamidi S, Chaussumier L, Mougenot N, et al. Mesenchymal stem cell delivery into rat infarcted myocardium using a porous polysaccharide-based scaffold: a quantitative comparison with endocardial injection. Tissue Eng Part A. 2012; 18: 35-44.
72. Sivasubramanian M, Thambi T, Park JH. Mineralized cyclodextrin nanoparticles for sustained protein delivery. Carbohydr Polym. 2013; 97: 643-9.